3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
49
Phase 1
22
Phase NA
13
Phase 1/2
8
Phase 3
4
Phase EARLY_PHASE1
2
Phase 4
1
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
91
Neoplasms
75
Prostatic Neoplasms
54
Carcinoma, Hepatocellular
53
Colorectal Neoplasms
49
Leukemia, Myeloid, Acute
41
Stomach Neoplasms
36
Carcinoma, Non-Small-Cell Lung
36
Precursor Cell Lymphoblastic Leukemia-Lymphoma
34
Neoplasm Metastasis
29
Pancreatic Neoplasms
27
Lung Neoplasms
26
Rectal Neoplasms
23
Multiple Myeloma
21
Hematologic Neoplasms
21
Head and Neck Neoplasms
20
Colonic Neoplasms
20
Recurrence
19
Lymphoma
19
Leukemia
19
Polycystic Ovary Syndrome
16
Liver Neoplasms
14
Esophageal Neoplasms
14
Brain Neoplasms
13
Myelodysplastic Syndromes
12
Melanoma
12
Endometrial Neoplasms
12
Uterine Cervical Neoplasms
11
Motor Activity
11
Fatigue
11
Interventions
pertuzumab
1
Trastuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
OTHER
×
Salivary Gland Neoplasms
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled